ALR
Alere Inc.
Healthcare, Event Driven/Special Sit
04/08/2013
Presented
| Date | 04/04/2013 |
| Price | $25.49 |
| Market Cap | $2.07B |
| Ent Value | $6.06B |
| P/E Ratio | N/A |
| Book Value | $21.38 |
| Div Yield | N/A |
| Shares O/S | 81.20M |
| Ave Daily Vol | 650,000 |
| Short Int | 4.52% |
Current
| Price | $1.32 |
| Market Cap | $0.04B |
| Alere Inc. provides point-of-care diagnostics and services for infectious and cardiometabolic diseases, and toxicology and in the United States and internationally. It operates in three segments: Professional Diagnostics, Patient Self-Testing, and Consumer Diagnostics. The Professional Diagnostics segment provides diagnostic test products and other in vitro diagnostic tests to medical professionals and laboratories for detection of diseases and conditions in the areas of viral hepatitis; respiratory syncytial virus; influenza; pneumonia; tuberculosis; human immunodeficiency virus/acquired immunodeficiency syndrome; gastrointestinal disease; vector-borne diseases, such as malaria and dengue; and herpes and other sexually-transmitted diseases, as well as diabetes, high blood pressure, high cholesterol, metabolic syndrome, coronary artery disease, heart attack, and heart failure and stroke. The Patient-Self Testing segment provides home monitoring patient self-testing services that support anticoagulation management through frequent self-testing by patients who take warfarin to control their risk for stroke and clotting disorders. The Consumer Diagnostics segment provides products for over-the-counter pregnancy and fertility/ovulation test markets; and over-the-counter drug tests for at-home testing and cholesterol monitoring under the First Check brand name, as well as vaginal gel for the treatment of bacterial vaginosis without antibiotics. Alere Inc. markets its professional diagnostic products to hospitals, reference laboratories, physician offices, and other point-of-care settings through its sales force and distribution networks; and First Check consumer drug testing products through retail drug stores, drug wholesalers, groceries, and mass merchandisers. The company was formerly known as Inverness Medical Innovations, Inc. and changed its name to Alere Inc. in July 2010. Alere Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts. |
Highlights
The presenter likes ALR at current levels given its relative underperformance and the potential for the company to finally leave its manufacturing issues in the rear-view mirror. Although there is no current event to speak of, he outlined the three ways investors could win owning ALR shares, and suggested an appropriate target price is north of $40 per-share (~60% upside) within the next 12-18 months.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.